CD274 and neoplasm: PD-L1 status has been demonstrated to significantly correlate with response and survival improvement from anti-PD-1/PD-L1 immunotherapy in UC patients [13], while there is no convincing evidence whether PD-L1 expression in tumour cells (TCs) or TIICs with a cut-off value of 5% or 1% could predict the prognosis and response.